Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Randomized, Phase 3 Study of the Contraceptive Efficacy and Safety of Agile Transdermal Contraceptive Delivery System in Comparison to an Oral Contraceptive (OC) Containing 150 mcg LNG and 30 mcg EE

Trial Profile

An Open-Label, Randomized, Phase 3 Study of the Contraceptive Efficacy and Safety of Agile Transdermal Contraceptive Delivery System in Comparison to an Oral Contraceptive (OC) Containing 150 mcg LNG and 30 mcg EE

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 08 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ethinylestradiol/levonorgestrel (Primary) ; Ethinylestradiol/levonorgestrel
  • Indications Pregnancy
  • Focus Registrational; Therapeutic Use
  • Acronyms NEW CHOICE II
  • Sponsors Agile Therapeutics
  • Most Recent Events

    • 22 Dec 2017 According to an Agile Therapeutics media release, the Company has submitted an amendment to the NDA in response to an information request from the FDA on the issues related to quality adhesion test methods cited in the CRL. The facility also provided the FDA responses addressing each of the observations made during the FDA's facility inspection. The CRL acknowledges receipt of the Company's NDA amendment and states that the amendment was not reviewed prior to the FDA's action.
    • 22 Dec 2017 According to an Agile Therapeutics media release, the U.S. Food and Drug Administration issued a complete response letter (CRL) in response to the New Drug Application (NDA) resubmission for Twirla (AG200-15). The CRL states that the FDA has determined that it cannot approve the NDA in its present form. The CRL recommends that the Company address the implications of clinical trial subject patch compliance and the withdrawal and dropout rates and does not identify any specific safety issues.
    • 22 Dec 2017 According to an Agile Therapeutics media release, the CRL identifies deficiencies relating to quality adhesion test methods and also noted that observations identified during an inspection of a facility of the Company's third-party manufacturer, Corium International Inc., (Corium), for the Twirla NDA must be resolved. The CRL also questions the in vivo adhesion properties of Twirla and their potential relationship to the SECURE phase 3 clinical trial results.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top